Back to results
US 12,215,163 B2Granted
CD25 antibodies
AssigneeiBio, Inc.
InventorsPhung Tu Gip, Bing Li, Matthew P. Greving, Matt Lundberg, Mohan Srinivasan
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeiBio, Inc.
InventorsPhung Tu Gip, Bing Li, Matthew P. Greving, Matt Lundberg, Mohan Srinivasan
Estimating the term…
Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases, and in certain aspects: disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor, bind to a different epitope than to which Daclizumab or Baciliximab bind, exhibit a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4, and/or exhibit a higher affinity of binding to CD25 at a pH of about 6.5.
A monoclonal CD25 antibody which binds to human CD25 comprising:
Dependencies are inferred from the claim text.